Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from LABORATORIO REIG JOFRE ( (ES:RJF) ) is now available.
Reig Jofre closed 2024 with a record net profit of 10.5 million euros, marking a 7% increase in revenues to 339 million euros, driven by strong demand for its dermatology, osteoarticular, and antibiotic products. The company’s global expansion strategy has been successful, with international sales now representing 59% of total revenues, and the opening of a new subsidiary in the Czech Republic further diversifying its income. Strategic investments in biotechnology and production capacity have bolstered its financial strength, reducing net financial debt and enhancing profitability, as evidenced by an 8% growth in EBITDA.
More about LABORATORIO REIG JOFRE
Laboratorio Reig Jofre is a pharmaceutical company listed on the Spanish stock exchange, specializing in antibiotics, high-tech sterile injectables, and prescription products in dermatology and osteoarticular. The company is focused on global expansion and innovation, with significant operations outside of Spain, particularly in Central Europe, Asia, and strategic markets like Sweden.
YTD Price Performance: 0.79%
Average Trading Volume: 456
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €212.9M
For an in-depth examination of RJF stock, go to TipRanks’ Stock Analysis page.